Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Emergent BioSolutions Inc. Director's Dealing 2013

Apr 19, 2013

32870_dirs_2013-04-19_1d3844e2-a3db-48e6-81ee-07454f790f15.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2013-03-08

Reporting Person: El-Hibri Fuad (Director, Chairman, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-03-08 Common Stock F 3818 $15.22 Disposed 1841752 Direct
2013-03-12 Common Stock F 1463 $14.67 Disposed 1840289 Direct
2013-03-12 Common Stock A 20902 Acquired 1861191 Direct

Footnotes

F1: This amendment on Form 4/A is being filed to correct an overstatement of 590 shares in the amount of securities disposed of by the reporting person and to correct the resulting amount of securities beneficially owned by the reporting person following such disposition. Except as described in footnotes 2 and 4, there are no other changes from the information originally reported on the Form 4 as originally filed on March 12, 2013.

F2: This amendment on Form 4/A is being filed to correct an overstatement of 254 shares in the amount of securities disposed of by the reporting person and to correct the resulting amount of securities beneficially owned by the reporting person following such disposition. Except as described in footnotes 1 and 4, there are no other changes from the information originally reported on the Form 4 as originally filed on March 12, 2013.

F3: These restricted stock units vest in three equal annual installments beginning on the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

F4: Adjusted to reflect the correct total number of securities beneficially owned by the reporting person after giving effect to the corrections described in footnotes 1 and 2. Except as described in footnotes 1 and 2, there are no other changes from the information originally reported on the Form 4 as originally filed on March 12, 2013.

F5: Mr. El-Hibri's direct holdings include restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.